BioSpace News Archive

Twin Health, makers of the Whole Body Digital Twin™ precision health service, today announced $140 million in Series C funding as it scales its service in the U.S. and globally.

Citius Pharmaceuticals, Inc. today announced that it will present at two investor conferences during the month of October 2021.

Flightpath Biosciences, Inc, a biotechnology company advancing microbiome-sparing therapeutics and diagnostics for infectious diseases, licensed a developmental antibiotic FP-100 acting selectively against a range of spirochetal pathogens from Northeastern University.

PreciseMDX, the leading end-to-end digital health platform for laboratories that automates and simplifies the diagnostic testing experience, announces today digital shipping kits for at-home or on-site diagnostic tests designed to streamline testing for patients, labs, and clinicians.

Canon Medical announced that due to recent developments in the Covid-19 pandemic, it will be attending all further relevant, major US-based global conferences in 2021, with a digital presence only.

ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the company’s Paradise™ Ultrasound Renal Denervation System (the “Paradise™ System”) is now available for the treatment of uncontrolled hypertension in Germany.

Progenity, Inc., an innovative biotechnology company, announced the closing of its previously announced registered direct offering of 13,333,334 shares of the Company’s common stock, at a purchase price of $1.50 per share, priced at a premium to market under Nasdaq rules for gross proceeds of approximately $20 million, before deducting the placement agent’s fees and other offering expenses.

Catalyst OrthoScience Inc., a medical device company focused on the upper extremity orthopedics market, has raised $12.3 million in an oversubscribed Series D financing round led by River Cities Capital and Mutual Capital Partners.

Haemonetics Corporation announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, November 9, 2021.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that on October 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 106,350 shares of Curis common stock to five new employees, with a grant date of October 1, 2021.